Key facts
- This page summarizes Mark Mcdade's Form 4 filing for Icosavax, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Apr 2022, 16:10.
Mark Mcdade - 01 Apr 2022 Form 4 Insider Report for Icosavax, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Apr 2022
- Net transaction value
- +$299,798
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2022, 16:10:09 UTC
- Next SEC filing
- 13 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark McDade
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Mcdade filed Form 4 for Icosavax, Inc. on 05 Apr 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$299,798.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ICVX
transaction
Common Stock
Purchase
- Transaction value
- $299,798
- Shares
- +42,225
- Change %
- +527%
- Price
- $7.10
- Shares after
- 50,243
- Date
- 01 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
ICVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,510,228
- Date
- 01 Apr 2022
- Ownership
- Qiming U.S. Healthcare Fund II, L.P.
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.70 to $7.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F2
The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the sole general partner of Qiming. The Reporting Person is a managing member of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.